Chinese vaccine developer CanSino targets ‘high disease burden’ nations for Covid-19 trials on health care concerns

• The company’s phase three trial of its Ad5-nCoV vaccine candidate is being tested on some 40,000 participants in Russia, Saudi Arabia, Pakistan and Mexico
• The last participant in the trial is expected to get the jab at the end of November, before the tests are wrapped up July 31 next year